Andreas Argyrides

Andreas Argyrides inquired about the market opportunity for ralinepag, expectations for advanced outcomes next year, and its potential for combination therapies.

Answer

Martine Rothblatt, Founder, Chairman, and CEO, highlighted ralinepag's strong outcomes trial enrollment, best-in-class open-label 6-minute walk distances, long patent life (around 2040), once-daily oral dosing, and its potency. She also noted impressive synergy with sotatercept and formulation flexibility for future combination treatments.

Andreas Argyrides inquired about the market opportunity for ralinepag, its potential for combination therapies, and expectations for advanced outcomes next year.

Answer

Martine Rothblatt, Founder, Chairman, and CEO, highlighted ralinepag's strong performance, successful enrollment in its outcomes trial, and best-in-class open-label six-minute walk distances. She emphasized its long patent life until approximately 2040, its once-daily oral dosing, and its potency as a prostacyclin. Martine also noted the synergy observed between sotatercept and treprostinil, suggesting similar potential for ralinepag, and mentioned significant formulation flexibility for future opportunities.